Free Trial
→ Trump to unlock 15-figure fortune for America (May 3rd) ? (From Paradigm Press) (Ad) Buy XENE Stock  Free XENE Stock Alerts

Xenon Pharmaceuticals (XENE) Financials

Xenon Pharmaceuticals logo
$33.44 +2.04 (+6.50%)
As of 04/14/2025 04:00 PM Eastern
Compare
Annual Income Statements for Xenon Pharmaceuticals

Annual Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -16 -23 -31 -32 -40 -28 -77 -125 -182 -234
Consolidated Net Income / (Loss)		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234
Net Income / (Loss) Continuing Operations		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234
Total Pre-Tax Income 		-16 -23 -32 -35 -42 -29 -79 -125 -183 -238
Total Operating Income		 -9.36 -25 -33 -38 -43 -31 -79 -129 -214 -279
Total Gross Profit		 16 1.80 0.31 -6.00 6.83 32 18 9.43 0.00 0.00
Total Revenue		 16 1.80 0.31 0.00 6.83 32 18 9.43 0.00 0.00
Operating Revenue		 16 1.80 0.31 - 6.83 32 18 9.43 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 6.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 25 27 33 32 50 63 97 139 214 279
Selling, General & Admin Expense		 9.79 6.79 7.31 8.41 11 13 22 33 47 69
Research & Development Expense		 15 20 26 24 39 51 75 106 168 210
Total Other Income / (Expense), net		 -6.39 1.82 0.48 3.52 1.20 2.20 0.11 3.89 31 41
Interest & Investment Income		 0.54 0.50 0.48 1.22 2.35 2.28 0.47 8.71 28 42
Other Income / (Expense), net		 -6.93 1.32 0.00 3.70 0.28 1.40 -0.36 -4.83 3.75 -1.06
Income Tax Expense		 - - - -0.02 -0.02 -0.26 -0.01 0.12 -0.29 -4.09
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 -2.88 -1.57 -0.82 -1.80 -0.44 0.00 0.00
Basic Earnings per Share		 ($1.10) ($1.48) ($1.71) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01)
Weighted Average Basic Shares Outstanding		 14.28M 15.49M 17.99M 19.43M 25.94M 34.54M 43.63M 60.54M 66.89M 77.89M
Diluted Earnings per Share		 ($1.10) ($1.48) ($1.72) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01)
Weighted Average Diluted Shares Outstanding		 14.28M 15.49M 18.00M 19.43M 25.94M 34.54M 43.63M 60.54M 66.89M 77.89M
Weighted Average Basic & Diluted Shares Outstanding		 14.30M 17.94M 18.00M 19.43M 25.94M 34.54M 43.63M 63.04M 75.43M 76.54M

Quarterly Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -37 -37 -42 -49 -48 -44 -48 -58 -59 -69
Consolidated Net Income / (Loss)		 -37 -37 -42 -47 -48 -45 -48 -58 -63 -66
Net Income / (Loss) Continuing Operations		 -37 -37 -42 -47 -48 -45 -48 -58 -63 -66
Total Pre-Tax Income 		-38 -36 -41 -48 -49 -45 -48 -58 -63 -70
Total Operating Income		 -38 -43 -49 -56 -56 -54 -59 -69 -74 -77
Total Operating Expenses		 38 43 49 56 56 54 59 69 74 77
Selling, General & Admin Expense		 8.83 8.50 9.54 12 13 13 15 19 17 18
Research & Development Expense		 29 35 40 44 43 41 44 50 57 59
Total Other Income / (Expense), net		 0.39 7.08 7.61 7.94 7.07 8.75 12 11 11 7.94
Interest & Investment Income		 3.07 4.46 5.42 6.52 6.98 8.69 11 11 10 9.42
Other Income / (Expense), net		 -2.68 2.61 2.19 1.42 0.08 0.06 0.17 0.01 0.24 -1.48
Income Tax Expense		 -0.59 1.14 0.29 -0.22 -0.16 -0.21 0.41 -0.33 -0.32 -3.85
Basic Earnings per Share		 ($0.57) ($0.59) ($0.63) ($0.72) ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83)
Weighted Average Basic Shares Outstanding		 65.47M 60.54M 65.72M 65.86M 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M
Diluted Earnings per Share		 ($0.57) ($0.59) ($0.63) ($0.72) ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83)
Weighted Average Diluted Shares Outstanding		 65.47M 60.54M 65.72M 65.86M 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M
Weighted Average Basic & Diluted Shares Outstanding		 62.54M 63.04M 63.56M 64.15M 65.43M 75.43M 75.47M 75.76M 76.24M 76.54M

Annual Cash Flow Statements for Xenon Pharmaceuticals

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -13 -42 3.39 48 -43 20 131 -118 91 -5.93
Net Cash From Operating Activities		 -18 -20 -29 -35 -4.71 -48 -70 -101 -151 -181
Net Cash From Continuing Operating Activities		 -18 -20 -29 -35 -4.71 -48 -70 -101 -151 -182
Net Income / (Loss) Continuing Operations		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234
Consolidated Net Income / (Loss)		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234
Depreciation Expense		 1.04 0.86 0.65 0.59 0.43 0.64 0.91 1.41 2.06 2.56
Amortization Expense		 0.00 0.00 0.01 0.28 0.53 0.22 - 0.82 - 1.25
Non-Cash Adjustments To Reconcile Net Income		 11 0.86 0.76 -1.13 2.54 6.23 11 23 24 43
Changes in Operating Assets and Liabilities, net		 -14 1.71 0.56 0.03 33 -26 -2.59 -1.28 5.61 5.71
Net Cash From Investing Activities		 10 -48 24 -29 -66 -17 -247 -293 -111 165
Net Cash From Continuing Investing Activities		 10 -48 24 -29 -66 -17 -247 -293 -111 165
Purchase of Property, Plant & Equipment		 -0.55 -0.28 -0.32 -0.51 -1.24 -2.64 -2.05 -2.89 -5.62 -3.08
Purchase of Investments		 0.00 -48 -28 -77 -140 -229 -389 -551 -794 -532
Sale and/or Maturity of Investments		 11 0.00 53 49 76 215 145 261 688 700
Net Cash From Financing Activities		 0.28 24 7.07 112 28 86 448 278 354 12
Net Cash From Continuing Financing Activities		 0.28 24 7.07 112 28 86 448 278 354 12
Issuance of Common Equity		 0.28 24 0.18 103 28 103 448 278 353 12
Other Financing Activities, net		 - - - - - - - 0.71 0.04 0.05
Effect of Exchange Rate Changes		 -5.74 1.89 0.75 - 0.41 -0.59 -0.59 -2.48 0.38 -1.67

Quarterly Cash Flow Statements for Xenon Pharmaceuticals

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -266 -46 12 -4.96 35 49 -90 78 -49 55
Net Cash From Operating Activities		 -30 -35 -34 -33 -48 -35 -43 -33 -51 -54
Net Cash From Continuing Operating Activities		 -30 -36 -34 -33 -48 -35 -43 -33 -52 -54
Net Income / (Loss) Continuing Operations		 -37 -37 -42 -47 -48 -45 -48 -58 -63 -66
Consolidated Net Income / (Loss)		 -37 -37 -42 -47 -48 -45 -48 -58 -63 -66
Depreciation Expense		 0.36 0.30 0.35 0.60 1.73 -0.63 0.60 0.66 0.67 0.63
Amortization Expense		 - - - - - - - - - 2.11
Non-Cash Adjustments To Reconcile Net Income		 9.00 0.10 4.11 6.97 7.95 4.58 9.40 15 12 6.54
Changes in Operating Assets and Liabilities, net		 -2.61 0.52 2.85 6.67 -3.45 -0.46 -5.25 9.76 -1.23 2.44
Net Cash From Investing Activities		 -234 -12 47 28 54 -240 -46 111 1.98 99
Net Cash From Continuing Investing Activities		 -234 -12 47 28 54 -240 -46 111 1.98 99
Purchase of Property, Plant & Equipment		 -0.39 -1.75 -2.21 -2.13 -1.20 -0.08 -0.19 -1.51 -0.59 -0.78
Purchase of Investments		 -295 -115 -108 -162 -147 -377 -177 -125 -164 -66
Sale and/or Maturity of Investments		 61 105 157 192 202 137 131 237 167 166
Net Cash From Financing Activities		 0.70 0.01 0.00 - 30 324 0.00 - - 12
Net Cash From Continuing Financing Activities		 0.70 0.01 0.00 - 30 324 0.00 - - 12
Issuance of Common Equity		 -277 277 0.00 - - 324 0.00 - - 12

Annual Balance Sheets for Xenon Pharmaceuticals

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 64 67 46 122 148 189 572 754 965 798
Total Current Assets		 61 66 45 121 145 182 559 600 645 635
Cash & Equivalents		 59 17 20 68 25 45 176 57 149 143
Short-Term Investments		 0.00 47 23 52 117 132 376 535 489 484
Accounts Receivable		 0.32 0.20 0.44 0.15 0.81 1.82 2.77 0.99 0.87 1.47
Prepaid Expenses		 1.90 1.33 0.72 1.88 2.70 2.96 4.48 7.23 6.01 6.89
Plant, Property, & Equipment, net		 1.99 1.40 1.07 0.99 1.66 3.55 4.47 6.50 9.65 10
Total Noncurrent Assets		 1.09 0.41 0.23 0.11 1.17 3.85 8.52 147 310 153
Long-Term Investments		 - - - - - - 0.00 129 293 127
Noncurrent Deferred & Refundable Income Taxes		 - - - 0.11 0.24 0.52 0.47 0.51 0.80 9.67
Other Noncurrent Operating Assets		 1.09 0.41 0.23 - 0.93 3.33 8.06 18 17 15
Total Liabilities & Shareholders' Equity		 64 67 46 122 148 189 572 754 965 798
Total Liabilities		 2.92 3.59 10 19 56 18 22 33 37 43
Total Current Liabilities		 2.78 3.59 4.08 4.12 43 15 14 23 27 36
Accounts Payable		 2.63 3.59 3.38 4.12 8.82 11 14 22 26 34
Other Current Liabilities		 - - - - 0.17 0.27 0.61 0.49 1.30 1.37
Total Noncurrent Liabilities		 0.13 0.00 6.10 15 12 3.05 7.65 9.95 9.60 7.65
Other Noncurrent Operating Liabilities		 0.13 - - - 0.74 3.05 7.65 9.95 9.60 7.65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 61 64 36 103 92 171 550 721 928 755
Total Preferred & Common Equity		 61 64 36 103 92 171 550 721 928 755
Total Common Equity		 61 64 36 96 84 164 542 721 928 755
Common Stock		 182 208 210 304 335 443 901 1,207 1,593 1,656
Retained Earnings		 -120 -143 -173 -208 -250 -278 -357 -483 -665 -899
Accumulated Other Comprehensive Income / (Loss)		 -0.99 -0.99 -0.99 -0.99 -0.99 -0.99 -0.99 -3.00 -0.08 -1.61

Quarterly Balance Sheets for Xenon Pharmaceuticals

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 776 720 685 671 919 884 836
Total Current Assets		 649 533 545 531 707 728 660
Cash & Equivalents		 103 70 65 100 59 137 88
Short-Term Investments		 535 458 475 427 641 585 566
Accounts Receivable		 2.48 2.22 2.12 0.81 0.83 0.85 0.94
Prepaid Expenses		 8.51 4.09 2.89 3.53 6.77 5.70 4.69
Plant, Property, & Equipment, net		 4.58 7.98 9.56 10 9.39 10 10
Total Noncurrent Assets		 122 179 131 130 202 146 166
Long-Term Investments		 114 160 113 112 186 129 149
Noncurrent Deferred & Refundable Income Taxes		 0.51 0.22 0.45 0.60 0.40 0.73 1.05
Other Noncurrent Operating Assets		 7.56 18 18 17 16 16 16
Total Liabilities & Shareholders' Equity		 776 720 685 671 919 884 836
Total Liabilities		 23 33 38 35 31 40 38
Total Current Liabilities		 16 22 28 25 22 31 30
Accounts Payable		 16 21 27 23 21 30 28
Other Current Liabilities		 0.00 1.19 1.22 1.25 1.32 1.35 1.39
Total Noncurrent Liabilities		 7.16 10 10 9.76 9.10 8.68 8.40
Other Noncurrent Operating Liabilities		 7.16 10 10 9.76 9.10 8.68 8.40
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 753 687 646 637 888 844 798
Total Preferred & Common Equity		 753 687 646 637 888 844 798
Total Common Equity		 753 687 646 637 888 844 798
Common Stock		 1,201 1,213 1,222 1,260 1,603 1,617 1,630
Retained Earnings		 -445 -524 -572 -620 -713 -771 -834
Accumulated Other Comprehensive Income / (Loss)		 -2.96 -1.82 -3.30 -2.95 -1.77 -2.21 1.34

Annual Metrics and Ratios for Xenon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -45.09% -88.43% -82.75% -100.00% 0.00% 371.02% -42.68% -48.83% -100.00% 0.00%
EBITDA Growth		 -215.68% -48.38% -40.99% -4.88% -24.23% 30.15% -170.09% -67.94% -58.07% -32.80%
EBIT Growth		 -230.88% -44.23% -38.61% -5.43% -23.86% 29.70% -165.35% -68.82% -56.98% -33.31%
NOPAT Growth		 -159.00% -165.11% -31.26% -16.78% -12.56% 26.90% -152.37% -63.49% -65.75% -30.48%
Net Income Growth		 -221.00% -45.99% -33.51% -12.35% -20.58% 30.67% -173.54% -58.94% -45.48% -28.48%
EPS Growth		 -133.54% -34.55% -16.22% 5.23% 5.52% 47.40% -118.52% -16.38% -32.52% -10.26%
Operating Cash Flow Growth		 -6,905.64% -8.09% -46.81% -20.88% 86.42% -920.87% -44.42% -45.36% -49.57% -20.04%
Free Cash Flow Firm Growth		 -265.17% 27.00% -50.02% -20.08% 110.81% -1,844.98% -18.13% -56.88% -57.38% -36.13%
Invested Capital Growth		 121.16% -110.28% -279.18% -7.32% -3,294.38% 83.33% 69.14% 141.82% -505.63% 117.00%
Revenue Q/Q Growth		 -9.58% -61.26% -53.65% -100.00% 95.11% 6.00% -7.12% -28.37% 0.00% 0.00%
EBITDA Q/Q Growth		 -49.14% -11.07% -6.28% -2.19% -6.69% -3.59% -19.56% -12.41% -7.24% -9.62%
EBIT Q/Q Growth		 -45.64% -10.01% -6.12% -2.47% -6.57% -3.19% -19.41% -12.98% -6.55% -9.93%
NOPAT Q/Q Growth		 -39.24% -13.02% -8.63% -1.07% -7.92% -4.42% -17.76% -16.71% -5.09% -9.31%
Net Income Q/Q Growth		 -48.73% -9.88% -7.20% -1.45% -7.27% -3.40% -20.17% -10.42% -4.20% -9.81%
EPS Q/Q Growth		 -280.33% -15.63% -8.18% 6.32% -5.48% 8.99% -8.59% -5.64% -2.25% -6.36%
Operating Cash Flow Q/Q Growth		 -14.53% 2.86% -8.16% -1.18% 85.15% -216.13% -12.27% -16.92% -1.80% -15.81%
Free Cash Flow Firm Q/Q Growth		 0.00% 8.98% -6.85% -3.22% 111.86% -199.77% -7.29% -17.43% -5.04% -13.16%
Invested Capital Q/Q Growth		 335.94% -34.62% -97.24% 8.20% -629.83% 36.64% -153.79% -22.96% -18.64% 109.09%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -97.94% -1,255.52% -10,262.06% 0.00% -608.92% -90.30% -425.49% -1,396.48% 0.00% 0.00%
Operating Margin		 -60.10% -1,376.43% -10,474.28% 0.00% -627.02% -97.31% -428.45% -1,368.91% 0.00% 0.00%
EBIT Margin		 -104.60% -1,303.44% -10,474.28% 0.00% -622.89% -92.97% -430.41% -1,420.06% 0.00% 0.00%
Profit (Net Income) Margin		 -101.12% -1,275.49% -9,872.67% 0.00% -609.09% -89.65% -427.85% -1,328.95% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 95.66% 99.93% 99.94% 99.12% 99.99% 100.09% 99.84% 98.29%
Interest Burden Percent		 96.67% 97.86% 98.54% 100.52% 97.84% 97.29% 99.41% 93.50% 86.87% 85.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,625.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,615.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,588.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.54% -36.81% -61.51% -49.55% -42.60% -21.90% -21.87% -19.72% -22.12% -27.85%
Cash Return on Invested Capital (CROIC)		 -847.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12,756.74% 0.00% -39,634.18%
Operating Return on Assets (OROA)		 -21.53% -35.76% -57.35% 0.00% -31.49% -17.75% -20.85% -20.20% 0.00% 0.00%
Return on Assets (ROA)		 -20.81% -34.99% -54.05% 0.00% -30.80% -17.12% -20.73% -18.91% 0.00% 0.00%
Return on Common Equity (ROCE)		 -23.54% -36.81% -61.51% -46.80% -39.23% -20.62% -21.40% -19.60% -22.12% -27.85%
Return on Equity Simple (ROE_SIMPLE)		 -25.81% -35.99% -85.45% -33.40% -45.22% -16.83% -14.34% -17.38% -19.66% -31.04%
Net Operating Profit after Tax (NOPAT)		 -6.55 -17 -23 -27 -30 -22 -55 -90 -150 -196
NOPAT Margin		 -42.07% -963.50% -7,331.99% 0.00% -438.91% -68.12% -299.91% -958.24% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.89% -9.16% -15.65% -11.15% -10.10% -4.57% -6.47% -5.50% -3.94% -4.61%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -12.53% -16.15% -25.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 62.82% 376.71% 2,351.45% 0.00% 158.19% 40.24% 119.15% 347.78% 0.00% 0.00%
R&D to Revenue		 97.27% 1,099.72% 8,222.83% 0.00% 568.82% 157.07% 409.30% 1,121.13% 0.00% 0.00%
Operating Expenses to Revenue		 160.10% 1,476.43% 10,574.28% 0.00% 727.02% 197.31% 528.45% 1,468.91% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -24 -33 -34 -43 -30 -79 -134 -210 -280
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -23 -32 -33 -42 -29 -78 -132 -208 -277
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.89 2.16 1.42 1.67 4.03 3.29 2.97 3.42 3.25 3.96
Price to Tangible Book Value (P/TBV)		 1.89 2.16 1.42 1.67 4.03 3.29 2.97 3.42 3.25 3.96
Price to Revenue (P/Rev)		 7.42 76.42 163.49 0.00 49.66 16.74 87.41 261.41 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 23.89 0.00 0.00 0.00 0.00 0.00 0.00 2,397.45 0.00 4,450.58
Enterprise Value to Revenue (EV/Rev)		 3.66 40.84 44.96 0.00 32.37 11.48 57.91 185.01 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 76.98 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.19 0.15 0.17 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.17 0.15 0.12 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -0.98 -1.01 -1.01 -1.18 -1.15 -1.01 -1.00 -1.00 -1.00
Leverage Ratio		 1.13 1.05 1.14 1.21 1.38 1.28 1.06 1.04 1.04 1.05
Compound Leverage Factor		 1.09 1.03 1.12 1.22 1.35 1.24 1.05 0.98 0.91 0.89
Debt to Total Capital		 0.00% 0.00% 15.92% 12.69% 14.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 1.64% 0.00% 4.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 14.28% 12.69% 10.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 6.54% 7.19% 4.51% 1.41% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 84.08% 80.77% 78.36% 95.49% 98.59% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.21 -0.45 -0.37 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 1.16 3.12 3.03 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.19 -0.45 -0.26 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.30 -0.56 -0.52 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 1.62 3.92 4.20 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.27 -0.56 -0.36 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 21.66 20.07 -3.53 2.84 1.21 16.76 43.85 44.77 48.12 39.64
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 5.55% 7.92% 5.87% 2.14% 0.61% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 21.88 18.31 10.98 29.46 3.34 12.30 39.03 26.44 23.65 17.85
Quick Ratio		 21.20 17.94 10.80 29.00 3.28 12.10 38.72 26.12 23.43 17.66
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -15 -22 -27 2.87 -50 -59 -93 -146 -199
Operating Cash Flow to CapEx		 -3,285.48% -7,013.26% -9,119.37% -6,848.92% -380.16% -1,824.95% -3,390.34% -3,490.95% -2,690.26% -5,898.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -19.05 2.00 -34.04 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -24.91 -3.29 -32.69 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -25.27 -4.15 -34.48 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.21 0.03 0.01 0.00 0.05 0.19 0.05 0.01 0.00 0.00
Accounts Receivable Turnover		 58.78 7.00 0.97 0.00 14.17 24.41 8.04 5.03 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 6.98 1.06 0.25 0.00 5.15 12.34 4.60 1.72 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 1.60 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 6.21 52.13 374.39 0.00 25.76 14.95 45.40 72.56 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 228.19 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 6.21 52.13 374.39 0.00 25.76 14.95 45.40 72.56 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2.38 -0.25 -0.93 -1.00 -34 -5.64 -1.74 0.73 -2.95 0.50
Invested Capital Turnover		 -3.51 1.69 -0.53 0.00 -0.39 -1.63 -4.99 -18.63 0.00 0.00
Increase / (Decrease) in Invested Capital		 14 -2.63 -0.68 -0.07 -33 28 3.90 2.47 -3.68 3.46
Enterprise Value (EV)		 57 74 14 63 221 369 1,068 1,745 2,083 2,234
Market Capitalization		 116 138 51 159 339 538 1,612 2,466 3,014 2,989
Book Value per Share		 $4.25 $3.57 $2.00 $3.79 $3.26 $4.67 $10.51 $11.54 $14.18 $9.90
Tangible Book Value per Share		 $4.25 $3.57 $2.00 $3.79 $3.26 $4.67 $10.51 $11.54 $14.18 $9.90
Total Capital		 61 64 43 118 108 171 550 721 928 755
Total Debt		 0.00 0.00 6.80 15 16 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 6.10 15 11 0.00 0.00 0.00 0.00 0.00
Net Debt		 -59 -64 -37 -104 -126 -177 -552 -721 -931 -754
Capital Expenditures (CapEx)		 0.55 0.28 0.32 0.51 1.24 2.64 2.05 2.89 5.62 3.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.57 -2.06 -2.23 -2.09 -35 -10.00 -7.08 -14 -20 -27
Debt-free Net Working Capital (DFNWC)		 58 62 41 117 106 167 545 578 618 600
Net Working Capital (NWC)		 58 62 41 117 101 167 545 578 618 600
Net Nonoperating Expense (NNE)		 9.20 5.63 7.90 7.87 12 6.93 24 35 33 39
Net Nonoperating Obligations (NNO)		 -59 -64 -37 -104 -126 -177 -552 -721 -931 -754
Total Depreciation and Amortization (D&A)		 1.04 0.86 0.66 0.87 0.95 0.86 0.91 2.22 2.06 3.81
Debt-free, Cash-free Net Working Capital to Revenue		 -3.64% -114.09% -716.72% 0.00% -515.76% -31.07% -38.38% -153.60% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 372.88% 3,443.65% 13,324.12% 0.00% 1,554.21% 519.19% 2,954.37% 6,122.49% 0.00% 0.00%
Net Working Capital to Revenue		 372.88% 3,443.65% 13,099.04% 0.00% 1,486.12% 519.19% 2,954.37% 6,122.49% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.10) ($1.48) ($1.71) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01)
Adjusted Weighted Average Basic Shares Outstanding		 14.28M 15.49M 17.99M 19.43M 34.96M 35.81M 51.92M 60.54M 66.89M 77.89M
Adjusted Diluted Earnings per Share		 ($1.10) ($1.48) ($1.72) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01)
Adjusted Weighted Average Diluted Shares Outstanding		 14.28M 15.49M 18.00M 19.43M 34.96M 35.81M 51.92M 60.54M 66.89M 77.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.48) ($1.71) ($1.63) ($1.54) ($0.81) ($1.77) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 14.40M 17.94M 18.00M 25.75M 25.94M 34.54M 43.63M 63.04M 75.43M 76.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.55 -17 -23 -27 -30 -22 -55 -90 -150 -196
Normalized NOPAT Margin		 -42.07% -963.50% -7,331.99% 0.00% -438.91% -68.12% -299.91% -958.24% 0.00% 0.00%
Pre Tax Income Margin		 -101.12% -1,275.49% -10,320.90% 0.00% -609.43% -90.45% -427.88% -1,327.70% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -24.64 -29.66 -20.32 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -19.10 -20.90 -14.89 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -25.00 -30.53 -22.11 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -19.47 -21.77 -16.68 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Xenon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -98.38% 0.00% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -160.65% -61.33% -131.88% -69.42% -33.19% -34.25% -25.31% -27.67% -35.09% -40.43%
EBIT Growth		 -159.46% -60.78% -129.35% -69.32% -36.27% -31.73% -25.64% -27.47% -32.08% -47.20%
NOPAT Growth		 -144.44% -74.45% -182.41% -83.49% -46.04% -23.92% -20.37% -24.23% -32.31% -44.29%
Net Income Growth		 -140.53% -46.28% -112.14% -52.32% -30.45% -19.65% -14.87% -22.05% -29.57% -46.81%
EPS Growth		 -58.33% -22.92% -80.00% -30.91% -28.07% -10.17% 1.59% -4.17% -10.96% -27.69%
Operating Cash Flow Growth		 -102.59% -70.59% -86.73% -96.95% -58.14% -0.20% -25.48% 1.63% -6.38% -53.63%
Free Cash Flow Firm Growth		 -47.99% -54.08% -107.34% -59.74% -25.51% -3.37% -46.22% -33.41% -36.55% -70.15%
Invested Capital Growth		 237.76% 141.82% -109.30% -134.56% -363.39% -505.63% 720.88% -14.21% -121.98% 117.00%
Revenue Q/Q Growth		 -75.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -27.83% 0.05% -15.68% -15.26% -0.49% -0.74% -10.39% -17.43% -6.33% -4.73%
EBIT Q/Q Growth		 -27.45% 0.21% -15.08% -15.67% -2.58% 3.53% -9.76% -17.36% -6.29% -7.51%
NOPAT Q/Q Growth		 -25.77% -13.65% -13.20% -13.40% -0.11% 3.57% -9.96% -17.04% -6.62% -5.16%
Net Income Q/Q Growth		 -19.23% -0.66% -11.58% -13.74% -2.11% 7.67% -7.13% -20.85% -8.40% -4.61%
EPS Q/Q Growth		 -3.64% -3.51% -6.78% -14.29% -1.39% 10.96% 4.62% -20.97% -8.00% -2.47%
Operating Cash Flow Q/Q Growth		 -80.23% -16.21% -5.13% 3.46% -44.72% 26.37% -21.75% 24.32% -56.51% -6.33%
Free Cash Flow Firm Q/Q Growth		 -26.91% -15.82% 8.36% -18.59% 0.29% 4.61% -29.63% -8.20% -2.06% -18.86%
Invested Capital Q/Q Growth		 138.65% -22.96% -150.00% -1,475.55% 56.60% -18.64% 176.53% -389.82% 15.65% 109.09%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -30,640.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -28,884.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -30,911.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -28,143.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 98.44% 103.14% 100.70% 99.54% 99.68% 99.54% 100.87% 99.43% 99.49% 94.47%
Interest Burden Percent		 92.49% 89.04% 88.43% 87.96% 87.44% 83.80% 80.71% 84.32% 85.94% 88.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -2,056,445.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2,056,442.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 2,055,911.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -533.61% -19.72% 0.00% -22.86% -25.19% -22.12% -23.95% -26.71% -29.75% -27.85%
Cash Return on Invested Capital (CROIC)		 -8,368.89% -12,756.74% 0.00% 0.00% 0.00% 0.00% -7,055.52% 0.00% 0.00% -39,634.18%
Operating Return on Assets (OROA)		 -782.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -712.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -529.50% -19.60% 0.00% -22.86% -25.19% -22.12% -23.95% -26.71% -29.75% -27.85%
Return on Equity Simple (ROE_SIMPLE)		 -15.08% 0.00% -21.46% -25.33% -27.50% 0.00% -21.25% -23.58% -26.75% 0.00%
Net Operating Profit after Tax (NOPAT)		 -27 -30 -34 -39 -39 -38 -41 -48 -52 -54
NOPAT Margin		 -20,219.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.09% -1.11% -1.21% -1.18% -1.36% -0.87% -0.84% -1.27% -1.56% -1.36%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.20% - - - -4.05% - - - -7.18%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,688.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 22,296.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 28,984.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -41 -41 -47 -54 -56 -54 -59 -69 -73 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -40 -47 -54 -54 -54 -58 -68 -73 -76
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.98 3.42 3.28 3.79 3.44 3.25 3.66 3.49 3.74 3.96
Price to Tangible Book Value (P/TBV)		 2.98 3.42 3.28 3.79 3.44 3.25 3.66 3.49 3.74 3.96
Price to Revenue (P/Rev)		 170.66 261.41 3,377.44 18,539.01 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1,582.58 2,397.45 0.00 0.00 0.00 0.00 1,045.10 0.00 0.00 4,450.58
Enterprise Value to Revenue (EV/Rev)		 113.55 185.01 2,348.54 13,598.16 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -1.00 -1.01 -1.00 -1.00 -1.00 -1.01 -1.01 -1.00
Leverage Ratio		 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.05 1.05 1.05
Compound Leverage Factor		 0.96 0.93 0.92 0.92 0.91 0.87 0.84 0.89 0.90 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 59.45 45.18 40.73 37.67 37.44 48.65 61.80 43.64 46.20 40.47
Noncontrolling Interest Sharing Ratio		 0.77% 0.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 41.78 26.44 23.71 19.34 21.46 23.65 31.82 23.27 22.21 17.85
Quick Ratio		 41.23 26.12 23.53 19.24 21.32 23.43 31.52 23.09 22.06 17.66
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -28 -33 -30 -36 -36 -34 -44 -48 -49 -58
Operating Cash Flow to CapEx		 -7,876.17% -2,016.55% -1,559.88% -1,557.48% -4,006.58% -45,385.90% -22,967.02% -2,158.45% -8,668.98% -6,945.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 4.61 5.03 0.26 0.06 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.98 1.72 0.11 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 79.22 72.56 1,405.63 6,424.83 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 79.22 72.56 1,405.63 6,424.83 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.95 0.73 -0.36 -5.74 -2.49 -2.95 2.26 -6.55 -5.53 0.50
Invested Capital Turnover		 101.71 -18.63 0.38 -0.03 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.63 2.47 -4.28 -3.29 -3.43 -3.68 2.62 -0.82 -3.04 3.46
Enterprise Value (EV)		 1,496 1,745 1,569 1,795 1,552 2,083 2,362 2,092 2,180 2,234
Market Capitalization		 2,248 2,466 2,256 2,447 2,191 3,014 3,247 2,943 2,983 2,989
Book Value per Share		 $12.10 $11.54 $10.90 $10.17 $9.92 $14.18 $11.77 $11.18 $10.53 $9.90
Tangible Book Value per Share		 $12.10 $11.54 $10.90 $10.17 $9.92 $14.18 $11.77 $11.18 $10.53 $9.90
Total Capital		 753 721 687 646 637 928 888 844 798 755
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -752 -721 -687 -652 -639 -931 -885 -851 -803 -754
Capital Expenditures (CapEx)		 0.39 1.75 2.21 2.13 1.20 0.08 0.19 1.51 0.59 0.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.55 -14 -16 -23 -20 -20 -15 -25 -24 -27
Debt-free Net Working Capital (DFNWC)		 634 578 511 516 506 618 685 697 630 600
Net Working Capital (NWC)		 634 578 511 516 506 618 685 697 630 600
Net Nonoperating Expense (NNE)		 10 7.06 7.39 8.52 9.48 7.16 6.60 9.55 11 11
Net Nonoperating Obligations (NNO)		 -752 -721 -687 -652 -639 -931 -885 -851 -803 -754
Total Depreciation and Amortization (D&A)		 0.36 0.30 0.35 0.60 1.73 -0.63 0.60 0.66 0.67 2.75
Debt-free, Cash-free Net Working Capital to Revenue		 -34.52% -153.60% -2,422.60% -17,532.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 4,810.86% 6,122.49% 76,476.05% 391,255.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 4,810.86% 6,122.49% 76,476.05% 391,255.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) ($0.59) ($0.63) ($0.72) ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83)
Adjusted Weighted Average Basic Shares Outstanding		 65.47M 60.54M 65.72M 65.86M 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M
Adjusted Diluted Earnings per Share		 ($0.57) ($0.59) ($0.63) ($0.72) ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83)
Adjusted Weighted Average Diluted Shares Outstanding		 65.47M 60.54M 65.72M 65.86M 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 62.54M 63.04M 63.56M 64.15M 65.43M 75.43M 75.47M 75.76M 76.24M 76.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -27 -30 -34 -39 -39 -38 -41 -48 -52 -54
Normalized NOPAT Margin		 -20,219.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -28,588.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Xenon Pharmaceuticals' Financials

When does Xenon Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Xenon Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Xenon Pharmaceuticals' net income changed over the last 9 years?

Xenon Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$234.33 million in 2024, rising from -$15.75 million in 2015. The previous period was -$182.39 million in 2023.

What is Xenon Pharmaceuticals's operating income?
Xenon Pharmaceuticals's total operating income in 2024 was -$279.30 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $279.30 million
How has Xenon Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Xenon Pharmaceuticals' total revenue changed from $15.58 million in 2015 to $0.00 in 2024, a change of -100.0%.

How much debt does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals' total liabilities were at $43.24 million at the end of 2024, a 17.2% increase from 2023, and a 1,383.2% increase since 2015.

How much cash does Xenon Pharmaceuticals have?

In the past 9 years, Xenon Pharmaceuticals' cash and equivalents has ranged from $17.10 million in 2016 to $175.69 million in 2021, and is currently $142.71 million as of their latest financial filing in 2024.

How has Xenon Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Xenon Pharmaceuticals' book value per share changed from 4.25 in 2015 to 9.90 in 2024, a change of 133.2%.

Remove Ads

Related Companies

This page (NASDAQ:XENE) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored